We focused on these representative tumor-agnostic mutations but excluded the mutations mainly detectable in AML such as FLT3 and IDH1, because the purpose of this review was to consider if the molecular-targeted drugs for solid tumors can be applicable for AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.